Swell Conversations

Assessing Contributors to Anxiety: The Unpredictability of HAE

Join us for an engaging discussion on potential contributors to patient anxiety related to hereditary angioedema (HAE). Our expert moderator, John Anderson, MD, clinical assistant professor at The University of Alabama at Birmingham and partner at AllerVie Health/AllerVie Clinical Research, welcomes Kimberly Poarch, PA-C, from Allergy & Asthma Specialists of Dallas. She will share emerging reports on factors impacting anxiety among patients with HAE and explore strategies to engage with patients in managing their disease. Additionally, clinical information about RUCONEST® (C1 esterase inhibitor [recombinant]), an approved on-demand HAE treatment option, will be highlighted. WHAT IS RUCONEST? RUCONEST® (C1 esterase inhibitor[recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. IMPORTANT SAFETY INFORMATION RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations. Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment. Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration. Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period. The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea. Before prescribing RUCONEST, please read the full Prescribing Information [https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf] including the Patient Product Information [https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf]. DISCLAIMER This educational program is sponsored by Pharming Healthcare, Inc. The speakers have been compensated for the presentation of this information. The information contained within this podcast is for educational purposes only and is not intended to be medical advice. Patient experiences may be discussed in this episode. It is important to recognize that these experiences may not be representative, as every patient has a unique disease course. This activity is not intended for Continuing Medical Education credits. EPISODE REFERENCE LIST 1. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214  2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 3. Burnette A, Anderson J, Longhurst H, et al. Anxiety associated with parenteral on-demand treatment for hereditary angioedema (HAE). Poster presented at: AAAAI 2023 Annual Meeting; February 24-27, 2023; San Antonio, TX. Poster 433. 4. Bernstein JA, Tyson C, Relan A, et al. Modeling cost-effectiveness of on-demand treatment for hereditary angioedema attacks. J Manag Care Spec Pharm. 2020;26(2):203-210. doi:10.18553/jmcp.2019.19217 5. Radojicic C, Burnette A, van Kooten S, et al. Patient-reported anxiety impacts utilization of injectable ondemand treatment of hereditary angioedema attacks. Poster presented at: ACAAI Annual Scientific Meeting; October 24-28, 2024; Boston, MA. ePoster R086. 6. Geng B, van Kooten S, Heckmann M, et al. Understanding why hereditary angioedema patients often do not carry their on-demand treatment with them. Poster presented at: ACAAI Annual Scientific Meeting; November 9-13, 2023; Anaheim, CA. 7. Kaplan AP, Kusumam J. Pathogenesis of hereditary angioedema: the role of bradykinin-forming cascade. Immunol Allergy Clin North Am. 2017;37(3):513-525. doi:10.1016/j.iac.2017.04.001 8. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in herediatry angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol. 1983;72(1):54-60. doi:10.1016/0091-6749(83)90052-0 9. Ruconest. Prescribing information. Pharming Healthcare, Inc; 2020. 10. Riedl MA, Bernstein JA, Li H, et al; Study 1310 Investigators. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163-169.e1. doi:10.1016/j.anai.2013.12.004 11. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-827.e14. doi:10.1016/j.jaci.2010.07.021 RUC-US-2025-0034

Managing HAE Attacks: Patient Behavior and the Decision to Treat

Welcome back to Swell Conversations: A Promotional HAE Series! John Anderson, MD, clinical assistant professor at The University of Alabama at Birmingham and partner at AllerVie Health, returns to chat with Andrew Smith, MD, MS, owner and physician at Allergy Associates of Utah, about emerging topics in the management of hereditary angioedema (HAE). This episode explores the decision-making patterns of patients who are considering the use of an on-demand HAE treatment and examines practical approaches to patient conversations, including navigating discussions about treatment decisions and encouraging adherence to published guidelines. Last, Drs Anderson and Smith discuss the possible role that RUCONEST® (C1 esterase inhibitor [recombinant]) may play in HAE management.   WHAT IS RUCONEST?  RUCONEST® (C1 esterase inhibitor[recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.  IMPORTANT SAFETY INFORMATION  RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations.  Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment.  Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration.  Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.   The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.   Before prescribing RUCONEST, please read the full Prescribing Information [https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf] including the Patient Product Information [https://www.ruconest.com/wp-content/uploads/Ruconest_PI_Apr2020.pdf].  DISCLAIMER  This educational program is sponsored by Pharming Healthcare, Inc. The speakers have been compensated for the presentation of this information. The information contained within this podcast is for educational purposes only and is not intended to be medical advice. Patient experiences may be discussed in this episode. It is important to recognize that these experiences may not be representative, as every patient has a unique disease course. This activity is not intended for Continuing Medical Education credits.   EPISODE REFERENCE LIST  1. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214   2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046  3. Christiansen S, O’Connor M, Ulloa J, et al. Delayed on-demand treatment of hereditary angioedema attacks: patient perceptions and associated barriers. Poster presented at: 2024 HAEi Regional Conference Americas; March 15-17, 2024; Panama City, Panama.  4. Sicherer SH, Simons FER; Section on Allergy and Immunology. Epinephrine for first-aid management of anaphylaxis. Pediatrics. 2017;139(3):e20164006. doi:10.1542/peds.2016-4006  5. Kaplan AP, Kusumam J. Pathogenesis of hereditary angioedema: the role of bradykinin-forming cascade. Immunol Allergy Clin North Am. 2017;37(3):513-525. doi:10.1016/j.iac.2017.04.001  6. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in herediatry angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol. 1983;72(1):54-60. doi:10.1016/0091-6749(83)90052-0  7. Ruconest. Prescribing Information. Pharming Healthcare, Inc; 2020.  8. Riedl MA, Bernstein JA, Li H, et al; Study 1310 Investigators. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163-169.e1. doi:10.1016/j.anai.2013.12.004  9. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-827.e14. doi:10.1016/j.jaci.2010.07.021 RUC-US-2025-0044

Bridging the Conversation: Redosing in HAE

In our final episode, hereditary angioedema (HAE) treatment redosing takes center stage during a discussion with Dr. John Anderson, clinical assistant professor at The University of Alabama at Birmingham and partner at AllerVie Health, and Dr. Raffi Tachdjian, associate clinical professor at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA). Drs. Anderson and Tachdjian will define redosing and explore misconceptions about redosing with acute HAE treatments. They will also discuss approaches to engage patients to help identify occurrences of redosing and management considerations for patients who consistently redose during HAE attacks. Finally, Drs. Anderson and Tachdjian will share clinical data related to redosing rates for RUCONEST® (C1 esterase inhibitor [recombinant]).  WHAT IS RUCONEST?  RUCONEST® (C1 esterase inhibitor[recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks.  IMPORTANT SAFETY INFORMATION  RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations.   Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment.   Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration.    Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.   The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.   Before prescribing RUCONEST, please read the full Prescribing Information [https://explorehae.com/wp-content/themes/explorehae/pdfs/ruconest-prescribing-information.pdf] including the Patient Product Information [https://explorehae.com/wp-content/themes/explorehae/pdfs/ruconest-prescribing-information.pdf].  DISCLAIMER  This educational program is sponsored by Pharming Healthcare, Inc. The speakers have been compensated for the presentation of this information. The information contained within this podcast is for educational purposes only and is not intended to be medical advice. Patient experiences may be discussed in this episode. It is important to recognize that these experiences may not be representative, as every patient has a unique disease course. This activity is not intended for Continuing Medical Education credits.   EPISODE REFERENCE LIST  1. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214  2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046 3. Bernstein JA, Tyson C, Relan A, et al. Modeling cost-effectiveness of on-demand treatment for hereditary angioedema attacks. J Manag Care Spec Pharm. 2020;26(2):203-210. doi:10.18553/jmcp.2019.19217 4. Magerl M, Zampeli V, Buttgereit T, Maurer M. Observations on real-world on-demand therapy use and outcome in patients with HAE due to C1-INH deficiency. Poster presented at: 4th Global Urticaria Forum; December 5-6, 2018; Berlin, Germany. 5. Balla Z, Ignácz B, Varga L, Kőhalmi KV, Farkas H. How Angioedema Quality of Life Questionnaire can help physicians in treating C1-inhibitor deficiency patients?. Clin Rev Allergy Immunol. 2021;61(1):50-59. doi:10.1007/s12016-021-08850-9 6. Ruconest. Prescribing information. Pharming Healthcare Inc; 2020. 7. Bernstein JA, Relan A, Harper JR, Riedl M. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2017;118(4):452-455. doi:10.1016/j.anai.2017.01.029

Instilling IV Confidence: Self-Administration in HAE

We’re back with John Anderson, MD, clinical assistant professor at The University of Alabama at Birmingham and partner at AllerVie Health, and Shahnaz Fatteh, MD, physician at the Asthma, Allergy Care Center of Florida, as they address clinician questions around intravenous (IV) self-administration within the context of RUCONEST® (C1 esterase inhibitor [recombinant]). RUCONEST can be administered via IV self-administration and is indicated to treat acute attacks in adult and adolescent patients with hereditary angioedema (HAE). We are delighted to welcome Kelly, a patient with HAE, who will share their experience learning to confidently self-administer an IV. Practical approaches for discussing IV self-administration with patients will be explored. In addition, an overview of RUCONEST training resources for IV self-administration will be highlighted. ----more---- WHAT IS RUCONEST?  RUCONEST® (C1 esterase inhibitor[recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. IMPORTANT SAFETY INFORMATION  RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations. Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment. Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration. Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.   The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.   Before prescribing RUCONEST, please read the full Prescribing Information [https://explorehae.com/wp-content/themes/explorehae/pdfs/ruconest-prescribing-information.pdf] including the Patient Product Information [https://explorehae.com/wp-content/themes/explorehae/pdfs/ruconest-prescribing-information.pdf].  DISCLAIMER  This educational program is sponsored by Pharming Healthcare, Inc. The speakers have been compensated for the presentation of this information. The information contained within this podcast is for educational purposes only and is not intended to be medical advice. Patient experiences may be discussed in this episode. It is important to recognize that these experiences may not be representative, as every patient has a unique disease course. This activity is not intended for Continuing Medical Education credits. EPISODE REFERENCE LIST  1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046  2. Jacobs J, Neeno T. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgrad Med. 2021;133(6):639-650. doi:10.1080/00325481.2021.1905364  3. Price G, Patel DA. Drug bioavailability. In: StatPearls Internet. StatPearls Publishing; 2023. Updated June 23, 2022. Accessed November 22, 2023. https://www.ncbi.nlm.nih.gov/books/NBK557852/  4. Ruconest. Prescribing information. Pharming Healthcare Inc; 2020.  5. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022;77(7):1961-1990. doi:10.1111/all.15214  6. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol. 1983;72(1):54-60.  7. What to expect. Ruconest. Accessed February 13, 2023. https://www.ruconest.com/patient-support/  8. How to self-administer. Ruconest. Accessed February 13, 2023. https://www.ruconest.com/dosing-administration/  9. Data on file. Pharming Healthcare Inc; 2019.

Painting the Picture: HAE Types and Management Approaches

Today on “Swell Conversations: A Promotional HAE Series,” John Anderson, MD, clinical assistant professor at The University of Alabama at Birmingham and partner at AllerVie Health, welcomes Douglas H. Jones, MD, practicing physician at the Tanner Clinic in Layton, Utah. In this episode, they break down the three types of hereditary angioedema (HAE) and share their personal approaches to disease management. Special attention is given to exploring HAE when C1 inhibitor (C1-INH) levels and function are deemed normal (ie, HAE-nl-C1INH). Drs Anderson and Jones also discuss the possible role that RUCONEST® (C1 esterase inhibitor [recombinant]) may play in HAE treatment regimens. ----more---- WHAT IS RUCONEST?  RUCONEST® (C1 esterase inhibitor[recombinant]) is indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. IMPORTANT SAFETY INFORMATION  RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products and for patients with a history of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor (C1-INH) preparations. Monitor patients for early signs of allergic or hypersensitivity reactions (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension, and/or anaphylaxis). If symptoms occur, discontinue RUCONEST and administer appropriate treatment. Serious arterial and venous thromboembolic (TE) events have been reported with plasma-derived C1-INH products. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, use of oral contraceptives or certain androgens, morbid obesity, and immobility. Monitor patients with known risk factors for TE events during and after RUCONEST administration. Appropriately trained patients may self-administer RUCONEST upon recognition of an HAE attack. Advise patients to seek medical attention if progress of any attack makes them unable to properly prepare or administer a dose of RUCONEST. No more than 2 doses should be administered within a 24-hour period.   The serious adverse reaction reported in clinical trials was anaphylaxis. The most common adverse reactions (incidence ≥2%) were headache, nausea, and diarrhea.   Before prescribing RUCONEST, please read the full Prescribing Information [https://explorehae.com/wp-content/themes/explorehae/pdfs/ruconest-prescribing-information.pdf] including the Patient Product Information [https://explorehae.com/wp-content/themes/explorehae/pdfs/ruconest-prescribing-information.pdf].  DISCLAIMER  This educational program is sponsored by Pharming Healthcare, Inc. The speakers have been compensated for the presentation of this information. The information contained within this podcast is for educational purposes only and is not intended to be medical advice. Patient experiences may be discussed in this episode. It is important to recognize that these experiences may not be representative, as every patient has a unique disease course. This activity is not intended for Continuing Medical Education credits. EPISODE REFERENCE LIST  1. Zafra H. Hereditary angioedema: a review. WMJ. 2022;121(1):48-53. doi:10.1016/j.jaip.2020.08.046  2. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046  3. Jones DH, Bansal P, Bernstein JA, et al. Clinical profile and treatment outcomes in patients with hereditary angioedema with normal C1 esterase inhibitor. World Allergy Organ J. 2022;15(1):100621. doi:10.1016/j.waojou.2021.100621  4. Jacobs J, Neeno T. The importance of recognizing and managing a rare form of angioedema: hereditary angioedema due to C1-inhibitor deficiency. Postgrad Med. 2021;133(6):639-650. doi:10.1080/00325481.2021.1905364  5. Riedl MA, Danese M, Danese S, et al. Hereditary angioedema with normal C1 inhibitor: US survey of prevalence and provider practice patterns. J Allergy Clin Immunol Pract. Published online January 30, 2023. doi:10.1016/j.jaip.2023.01.023  6. Bova M, Suffritti C, Bafunno V, et al. Impaired control of the contact system in hereditary angioedema with normal C1-inhibitor. Allergy. 2020;75(6):1394-1403. doi:10.1111/all.14160  7. Zanichelli A, Longhurst HJ, Maurer M, et al. Misdiagnosis trends in patients with hereditary angioedema from the real-world clinical setting. Ann Allergy Asthma Immunol. 2016;117(4):394-398. doi:10.1016/j.anai.2016.08.014  8. Ruconest. Prescribing information. Pharming Healthcare Inc; 2020.  9. Jones D, Zafra H, Anderson J. Managing diagnosis, treatment, and burden of disease in hereditary angioedema patients with normal C1-esterase inhibitor. J Asthma Allergy. 2023;16:447-460. doi:10.2147/JAA.S398333